The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium.
about
Risk of Hyponatraemia in Cancer Patients Treated with Targeted Therapies: A Systematic Review and Meta-Analysis of Clinical TrialsA five-factor biomarker profile obtained week 4-12 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2.Hyponatremia normalization as an independent prognostic factor in patients with advanced non-small cell lung cancer treated with first-line therapyThe best objective response of target lesions and the incidence of treatment-related hypertension are associated with the survival of patients with metastatic renal cell carcinoma treated with sunitinib: a Japanese retrospective studyPrevalence of Hyponatremia in Palliative Care Patients.Patients with ClearCode34-identified molecular subtypes of clear cell renal cell carcinoma represent unique populations with distinct comorbidities.Tumor suppression in basal keratinocytes via dual non-cell-autonomous functions of a Na,K-ATPase beta subunit.Prognostic factors for survival following initiation of second-line treatment with everolimus for metastatic renal cell carcinoma: evidence from a nationwide sample of clinical practice in the United States.Hyponatremia is a predictor of hospital length and cost of stay and outcome in cancer patients.Euvolemic hyponatremia in cancer patients. Report of the Hyponatremia Registry: an observational multicenter international study.Diagnosis of hyponatremia and increased risk of a subsequent cancer diagnosis: results from a nationwide population-based cohort study.The Danish experience with trabectedin treatment for metastatic sarcoma: Importance of hyponatremia.Basic Parameters of Blood Count, Serum Sodium, and Creatinine as Prognostic Factors for Renal Cell Carcinoma at Five-Year Follow-Up.
P2860
Q28551983-F5F5AE62-B35A-4741-AF74-16C9976DA04FQ33426559-AF3D401D-A55A-4919-8DBB-5429F48F3B13Q33618900-A0A2878A-6F6E-41F3-87E0-1DE6236C019AQ35918881-87421EE8-7E3B-4285-BF21-E89FD6ABCBE0Q35951966-380DA3A0-93E0-4232-B3DB-0F48FEB22B35Q36600872-55F04CA9-0EF2-4BE3-8F31-CCC7423CCA82Q37151552-E9701F80-D05A-4462-9D18-A45BF803205AQ41232235-0D509253-67FE-4F6B-8755-D6BF3D10B467Q41295884-8129701F-98AB-4542-9F55-343002CA5AE6Q42244095-BBD7BD79-CAE4-4ED7-809A-3B269062F141Q42515289-2C9FB73B-07EF-48DF-8821-9DD1AB1714E3Q44301485-60D51508-E78F-43A2-9C79-4E4B516CA35DQ55443604-5772CEDD-3CD6-4EAD-A851-7C5C784F7BB2
P2860
The impact of low serum sodium on treatment outcome of targeted therapy in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Cancer Database Consortium.
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
The impact of low serum sodium ...... ll Cancer Database Consortium.
@ast
The impact of low serum sodium ...... ll Cancer Database Consortium.
@en
The impact of low serum sodium ...... ll Cancer Database Consortium.
@nl
type
label
The impact of low serum sodium ...... ll Cancer Database Consortium.
@ast
The impact of low serum sodium ...... ll Cancer Database Consortium.
@en
The impact of low serum sodium ...... ll Cancer Database Consortium.
@nl
prefLabel
The impact of low serum sodium ...... ll Cancer Database Consortium.
@ast
The impact of low serum sodium ...... ll Cancer Database Consortium.
@en
The impact of low serum sodium ...... ll Cancer Database Consortium.
@nl
P2093
P2860
P50
P1433
P1476
The impact of low serum sodium ...... ll Cancer Database Consortium.
@en
P2093
Brian I Rini
Christian Kollmannsberger
Daniel Y C Heng
David F McDermott
Fabio A B Schutz
Jae Lyun Lee
Lori A Wood
Mary J Mackenzie
Min-Han Tan
Monica Sircar
P2860
P304
P356
10.1016/J.EURURO.2013.10.013
P407
P577
2013-10-26T00:00:00Z